Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $742.8 million.

  • Keros Therapeutics' Liabilities and Shareholders Equity rose 2822.72% to $742.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 5344.89%. This contributed to the annual value of $615.9 million for FY2024, which is 6644.44% up from last year.
  • Latest data reveals that Keros Therapeutics reported Liabilities and Shareholders Equity of $742.8 million as of Q3 2025, which was up 2822.72% from $757.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Liabilities and Shareholders Equity registered a high of $784.6 million during Q1 2025, and its lowest value of $226.7 million during Q2 2022.
  • In the last 5 years, Keros Therapeutics' Liabilities and Shareholders Equity had a median value of $356.3 million in 2023 and averaged $414.0 million.
  • Per our database at Business Quant, Keros Therapeutics' Liabilities and Shareholders Equity skyrocketed by 32535.32% in 2021 and then plummeted by 876.42% in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Liabilities and Shareholders Equity stood at $255.3 million in 2021, then grew by 20.19% to $306.8 million in 2022, then rose by 20.62% to $370.0 million in 2023, then skyrocketed by 66.44% to $615.9 million in 2024, then rose by 20.6% to $742.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $742.8 million for Q3 2025, versus $757.2 million for Q2 2025 and $784.6 million for Q1 2025.